MX2020012332A - Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo. - Google Patents

Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo.

Info

Publication number
MX2020012332A
MX2020012332A MX2020012332A MX2020012332A MX2020012332A MX 2020012332 A MX2020012332 A MX 2020012332A MX 2020012332 A MX2020012332 A MX 2020012332A MX 2020012332 A MX2020012332 A MX 2020012332A MX 2020012332 A MX2020012332 A MX 2020012332A
Authority
MX
Mexico
Prior art keywords
methods
glucosidase
expression cassettes
nucleic acids
lpha
Prior art date
Application number
MX2020012332A
Other languages
English (en)
Inventor
Xavier Anguela
Sean Armour
Jayme Nordin
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of MX2020012332A publication Critical patent/MX2020012332A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Abstract

La invención proporciona ácidos nucleicos que codifican la alfa-glucosidasa ácida (GAA). En ciertas modalidades, los ácidos nucleicos tienen más de aproximadamente 86% de identidad de secuencia con una secuencia seleccionada del grupo que consiste en cualquiera de las secuencias expuestas como SEC ID NOs: 1-5. En ciertas modalidades, los ácidos nucleicos que codifican la alfa-glucosidasa (GAA) contienen menos de 127 dinucleótidos CpG. También se proporcionan casetes de expresión, vectores, células y líneas celulares y métodos para usar dichos ácidos nucleicos que codifican la alfa-glucosidasa ácida (GAA).
MX2020012332A 2018-05-16 2019-05-15 Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo. MX2020012332A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862672419P 2018-05-16 2018-05-16
US201862734454P 2018-09-21 2018-09-21
PCT/US2019/032502 WO2019222411A1 (en) 2018-05-16 2019-05-15 Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same

Publications (1)

Publication Number Publication Date
MX2020012332A true MX2020012332A (es) 2021-02-26

Family

ID=68540790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012332A MX2020012332A (es) 2018-05-16 2019-05-15 Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo.

Country Status (16)

Country Link
US (1) US20210222141A1 (es)
EP (1) EP3794043A4 (es)
JP (1) JP2021523718A (es)
KR (1) KR20210021310A (es)
CN (1) CN112334489A (es)
AU (1) AU2019268363A1 (es)
BR (1) BR112020023393A2 (es)
CA (1) CA3100213A1 (es)
CL (1) CL2020002973A1 (es)
CO (1) CO2020015707A2 (es)
MX (1) MX2020012332A (es)
PE (1) PE20210337A1 (es)
PH (1) PH12020551957A1 (es)
SG (1) SG11202011191WA (es)
TW (1) TW202016310A (es)
WO (1) WO2019222411A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
US11970722B2 (en) * 2019-12-20 2024-04-30 Codexis, Inc. Engineered acid alpha-glucosidase variants
AU2022328531A1 (en) * 2021-08-20 2024-03-14 Joint Stock Company "Biocad" Method of obtaining a modified adeno-associated virus capsid
WO2023150623A2 (en) * 2022-02-02 2023-08-10 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013243949A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
PT2839014T (pt) * 2012-04-18 2021-03-19 Childrens Hospital Philadelphia ¿composição e métodos para transferência de genes altamente eficiente com a utilização de variantes de capsídeo de aav
EP3293259A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof

Also Published As

Publication number Publication date
JP2021523718A (ja) 2021-09-09
US20210222141A1 (en) 2021-07-22
BR112020023393A2 (pt) 2021-02-09
CL2020002973A1 (es) 2021-07-19
CA3100213A1 (en) 2019-11-21
EP3794043A4 (en) 2022-02-23
EP3794043A1 (en) 2021-03-24
AU2019268363A1 (en) 2021-01-07
CO2020015707A2 (es) 2021-03-19
TW202016310A (zh) 2020-05-01
PE20210337A1 (es) 2021-02-19
SG11202011191WA (en) 2020-12-30
CN112334489A (zh) 2021-02-05
PH12020551957A1 (en) 2021-09-20
KR20210021310A (ko) 2021-02-25
WO2019222411A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
MX2020012332A (es) Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo.
PH12019501335A1 (en) Thermostable cas9 nucleases
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX2020003092A (es) Vectores de adn no integrantes para la modificacion genetica de celulas.
NZ602416A (en) Optically-based stimulation of target cells and modifications thereto
NZ610301A (en) Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
MX2020005458A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
IL86480A0 (en) Recombinant dna coding for human proapolipoprotein a-i,expression vectors containing it and cells transformed by said expression vector
IL309801A (en) Use of protein domains interacting with the nucleosome to enhance targeted genome modification
PH12018501628A1 (en) Optimized factor viii genes
GB2582100A (en) CAS12C Compositions and methods of use
DK1824970T3 (da) Thricoderma reesei-glycoamylase og homologer heraf
GB201201178D0 (en) Novel enzymes
AR090417A1 (es) Plantas resistentes al glifosato y metodos asociados
CL2009002108A1 (es) Secuencia de adn que codifica una de secuencia aminoacidos con actividad farnesil pirofosfato sintetasa; vector que comprende dicha secuencia; celula huesped transformada con dicha secuencia; proceso de produccion de enzima para convertir isopentil pirofosfato a farnesil pirofosfato; y proceso para producir astaxantina (div. sol. no 891-99).
HK1125659A1 (en) Kdr peptides and vaccines comprising the same kdr
ATE448298T1 (de) Il-21-produktion in prokaryontischen wirten
MX2020000676A (es) Composiciones y metodos para tratar beta-hemoglobinopatias.
DK1165759T3 (da) Polypeptider, der har forgrenende enzymaktivitet, og nukleinsyrer, der koder for samme
WO2020047467A3 (en) Cardiac cell reprogramming with myocardin and ascl1
WO2016130628A8 (en) Griffithsin mutants
EA202190454A1 (ru) Новый crispr-ассоциированный белок и его применение
PH12017502323A1 (en) Novel xylanase
NZ601950A (en) Method for producing pyripyropene
EP3950939A3 (en) Lipase variants and polynucleotides encoding same